Infinity Pharmaceuticals to Present at Two Upcoming Conferences
08. September 2010 16:30 ET
|
Infinity Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Sept. 8, 2010 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) will be presenting at the Rodman & Renshaw Annual Global Investment Conference in New York on...
Infinity Highlights R&D Progress and Announces Second Quarter 2010 Financial Results
04. August 2010 06:30 ET
|
Infinity Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Aug. 4, 2010 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative drug discovery and development company, today detailed recent developments in its product...
Infinity to Present at BMO Healthcare Conference
29. Juli 2010 11:30 ET
|
Infinity Pharmaceuticals, Inc.
CAMBRIDGE, Mass., July 29, 2010 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative drug discovery and development company, today announced that Vito J. Palombella, Chief...
Infinity Announces Second Quarter 2010 Results Conference Call
28. Juli 2010 08:00 ET
|
Infinity Pharmaceuticals, Inc.
CAMBRIDGE, Mass., July 28, 2010 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative drug discovery and development company, announced today that management will host a...
Infinity and Intellikine Enter Agreement to Develop Oral Therapies Targeting PI3 Kinase Delta, Gamma
08. Juli 2010 08:00 ET
|
Infinity Pharmaceuticals, Inc.
Infinity Uses Scientific Expertise and Financial Strength to Enter New Therapeutic Area
Intellikine Retains Strategic Development and Commercial Rights in Oncology in Deal Valued Up to $488...
Infinity Initiates Second Clinical Trial of IPI-493, Its Oral Hsp90 Chaperone Inhibitor
24. Juni 2010 08:30 ET
|
Infinity Pharmaceuticals, Inc.
CAMBRIDGE, Mass., June 24, 2010 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative drug discovery and development company, today announced that patients are being enrolled...
Infinity Reports Results From Phase 2 Clinical Trial of IPI-504 in Non-Small Cell Lung Cancer
04. Juni 2010 08:30 ET
|
Infinity Pharmaceuticals, Inc.
CAMBRIDGE, Mass., June 4, 2010 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) today reported the results from its Phase 2 clinical trial of IPI-504, the company's i.v.-administered...
Infinity to Present at Jefferies Global Life Sciences Conference
02. Juni 2010 10:09 ET
|
Infinity Pharmaceuticals, Inc.
CAMBRIDGE, Mass., June 2, 2010 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative drug discovery and development company, today announced that Adelene Q. Perkins,...
Infinity Announces Addition to Senior Leadership Team
24. Mai 2010 08:39 ET
|
Infinity Pharmaceuticals, Inc.
CAMBRIDGE, Mass., May 24, 2010 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative drug discovery and development company, today announced that Winselow S. Tucker, Jr. has...
Infinity to Present Data From Its Anti-Cancer Programs at ASCO Meeting
20. Mai 2010 18:00 ET
|
Infinity Pharmaceuticals, Inc.
CAMBRIDGE, Mass., May 20, 2010 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative drug discovery and development company, today announced that data from its Hsp90...